AstraZeneca was awarded up to $486 million from the U.S. government for the late-stage development and large-scale manufacture of AZD7442, a cocktail of two monoclonal antibodies, for the potential treatment or prevention of SARS-CoV-2, the virus that causes COVID-19. The funding will be used for two Phase III trials and related development and manufacturing for the supply of AZD7442 doses in the U.S. One trial will evaluate the safety and efficacy of AZD7442 to prevent infection for up to 12...